CONSENSUS

Cooperative North Scandinavian Enalapril Survival Study

Patient / Population Intervention / Exposure Comparison Outcome

In 253 patients with NYHA IV heart failure, enalapril reduced 6-month mortality versus placebo.

253

Design

Double-blind RCT, terminated early

Endpoint

Mortality at 6 months

Relevance

Result26 % vs 44 % (40 % RRR). Effect maintained at 12 months.

CONSENSUS Trial Study Group. N Engl J Med. 1987;316(23):1429-1435. 10.1056/NEJM198706043162301

Discussion & critique

Small but transformative — opened the ACE inhibitor era for HF. Limited to severe HF; SOLVD generalised to milder disease.